Tech Company Financing Transactions
Advanced Biohealing Funding Round
On 2/27/2007, Advanced Biohealing raised $25.5 million in Series C financing from Safeguard Scientifics, Canaan Partners and Channel Medical Partners.
Transaction Overview
Company Name
Announced On
2/27/2007
Transaction Type
Venture Equity
Amount
$25,500,000
Round
Series C
Investors
Safeguard Scientifics (Lead Investor) (Gary Kurtzman)
Channel Medical Partners (Carol Winslow)
Proceeds Purpose
Proceeds from the financing will be used to execute the launch and expand the market for Dermagraft, approved by the U.S. Food and Drug Administration (FDA) as a treatment for full-thickness diabetic foot ulcers. Funding will also support the Company's clinical trials program, in-licensing activities and international expansion.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
36 Church Ln.
Westport, CT 06880
USA
Westport, CT 06880
USA
Phone
Website
Email Address
Overview
Advanced BioHealing (ABH) is a specialty biotechnology company focused on the development and marketing of cell-based and tissue-engineered products for wound care. We are a privately held company with two approved products: Dermagraft and TransCyte.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kevin Rakin
Chief Medical Officer
Jan Lessem
Chief Scientific Officer
Charles Hart
Controller
Marc Posel
Vice President
Therésa Dixon
Vice President
Dean Tozer
VP - Operations
Kathy McGee
VP - Sales
Keith O'Briant
Browse more venture capital transactions:
Prev: 2/27/2007: BiPar Sciences venture capital transaction
Next: 2/27/2007: Spadac venture capital transaction
Share this article
Where The Data Comes From
We do our best to document funding rounds that are announced publicly. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs